James

James Therapeutics is a biotechnology company focused on developing novel therapies for neurodegenerative diseases and cancer by targeting stress granule dynamics. The company's proprietary platform identifies small molecules that can modulate the formation and clearance of stress granules, which are linked to the progression of diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). By restoring normal RNA-binding protein function and cellular homeostasis, James Therapeutics aims to provide disease-modifying treatments for conditions with high unmet medical needs. The company is currently advancing its lead programs through pre-clinical development.